Neurotransmitter Dopamine Impacts Willingness to Work

Everyone knows that people vary substantially in how hard they are willing to work, but the origin of these individual differences in the brain remains a mystery. Now the veil has been pushed back by a new brain imaging study that has found an individual’s willingness to work hard to earn money is strongly influenced by the chemistry in three specific areas of the brain.

In addition to shedding new light on how the brain works, the research could have important implications for the treatment of attention-deficit disorder, depression, schizophrenia and other forms of mental illness characterized by decreased motivation.

The study was published May 2 in the Journal of Neuroscience and was performed by a team of Vanderbilt scientists including post-doctoral student Michael Treadway and Professor of Psychology David Zald.

Using a brain mapping technique called positron emission tomography (PETscan), the researchers found that “go-getters” who are willing to work hard for rewards had higher release of the neurotransmitter dopamine in areas of the brain known to play an important role in reward and motivation, the striatum and ventromedial prefrontal cortex.

On the other hand, “slackers” who are less willing to work hard for a reward had high dopamine levels in another brain area that plays a role in emotion and risk perception, the anterior insula.

“Past studies in rats have shown that dopamine is crucial for reward motivation,” said Treadway, “but this study provides new information about how dopamine determines individual differences in the behavior of human reward-seekers.”

The role of dopamine in the anterior insula came as a complete surprise to the researchers. The finding was unexpected because it suggests that more dopamine in the insula is associated with a reduced desire to work, even when it means earning less money. The fact that dopamine can have opposing effects in different parts of the brain complicates the picture regarding the use of psychotropic medications that affect dopamine levels for the treatment of attention-deficit disorder, depression and schizophrenia because it calls into question the general assumption that these dopaminergic drugs have the same effect throughout the brain.

The study was conducted with 25 healthy volunteers (52 percent female) ranging in age from 18 to 29. To determine their willingness to work for a monetary reward, the participants were asked to perform a button-pushing task. First, they were asked to select either an easy or a hard button-pushing task. Easy tasks earned $1 while the reward for hard tasks ranged up to $4. Once they made their selection, they were told they had a high, medium or low probability of getting the reward. Individual tasks lasted for about 30 seconds and participants were asked to perform them repeatedly for about 20 minutes.

“At this point, we don’t have any data proving that this 20-minute snippet of behavior corresponds to an individual’s long-term achievement,” said Zald, “but if it does measure a trait variable such as an individual’s willingness to expend effort to obtain long-term goals, it will be extremely valuable.”

The research is part of a larger project designed to search for objective measures for depression and other psychological disorders where motivation is reduced. “Right now our diagnoses for these disorders is often fuzzy and based on subjective self-report of symptoms,” said Zald. “Imagine how valuable it would be if we had an objective test that could tell whether a patient was suffering from a deficit or abnormality in an underlying neural system. With objective measures we could treat the underlying conditions instead of the symptoms.”

Further research is needed to examine whether similar individual differences in dopamine levels help explain the altered motivation seen in forms of mental illness such as depression and addiction. Additional research is under way to examine how medications specifically impact these motivational systems.

Robert Kessler, professor of radiology and radiological sciences, Ronald Cowan, associate professor of psychiatry, Joshua Buckholtz, assistant professor of psychology at Harvard, Neil Woodward, assistant professor of psychology, Rui Li, senior research specialist of radiology and radiological sciences, Sib Ansari, associate of radiology and radiological sciences, Ronald Baldwin, research associate professor of radiology and radiological sciences, and research assistant Ashley Schwartzman also contributed to the study.

Material adapted from Vanderbilt University.

About Christopher Fisher, PhD

Dr. Christopher Fisher, Managing Editor for The Behavioral Medicine Report, received his PhD in Clinical Health Psychology & Behavioral Medicine from University of North Texas. His clinical training emphasized biopsychosocial approaches to health and wellness, including Cognitive Behavioral Therapy (CBT), neurofeedback, biofeedback, cranial electrical stimulation (CES), and QEEG. He is Board Certified in Neurofeedback (BCN) by BCIA. Dr. Fisher also received a master’s degree in Clinical Psychology from Texas A&M - Corpus Christi.
Dr. Fisher maintains a private practice in Corpus Christi, Texas, and offers individual therapy, group therapy, peripheral biofeedback, and neurofeedback. You can learn more at http://www.christopherfisherphd.com. He also maintains an informational website for panic attacks (panic disorder) here: http://www.panicintervention.com
Dr. Fisher enjoys spending time with family, watching sports and movies, and outdoor activities.